Last reviewed · How we verify

Heparin fixed doses — Competitive Intelligence Brief

Heparin fixed doses (Heparin fixed doses) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

marketed Anticoagulant Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect inhibition) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Heparin fixed doses (Heparin fixed doses) — SANE-Society of Anesthesiology. Heparin is an anticoagulant that inhibits blood clotting by potentiating antithrombin III, which inactivates thrombin and other clotting factors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Heparin fixed doses TARGET Heparin fixed doses SANE-Society of Anesthesiology marketed Anticoagulant Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect inhibition)
Pradaxa dabigatran etexilate Generic (originally Boehringer Ingelheim) marketed Direct oral anticoagulant (DOAC) — direct thrombin inhibitor Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] 2010-10-19
Coumadin warfarin Generic (originally Wisconsin Alumni Research Foundation) marketed Vitamin K antagonist (anticoagulant) Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 1954-01-01
Heparin Sodium In Plastic Container Heparin Sodium Fresenius Kabi marketed Anticoagulant Antithrombin III; Coagulation Factors Xa and IIa 1939-01-01
Heparin Sodium In Plastic Container Heparin Sodium Fresenius Kabi marketed Anticoagulant Antithrombin III, Coagulation Factors Xa and IIa 1939-01-01
Heparin Sodium In Plastic Container Heparin Sodium Fresenius Kabi marketed Anticoagulant Antithrombin III; Coagulation Factors Xa and IIa 1939-01-01
Heparin Sodium In Plastic Container Heparin Sodium Fresenius Kabi marketed Anticoagulant Antithrombin III, Coagulation Factors Xa and IIa 1939-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

  1. Fresenius Kabi · 4 drugs in this class
  2. University of Sao Paulo · 3 drugs in this class
  3. Beijing Anzhen Hospital · 2 drugs in this class
  4. San Filippo Neri General Hospital · 2 drugs in this class
  5. Yong Seog Oh · 2 drugs in this class
  6. CCRF Consulting Co., Ltd. · 1 drug in this class
  7. Boston Scientific Corporation · 1 drug in this class
  8. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
  9. Faculty Hospital Kralovske Vinohrady · 1 drug in this class
  10. Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Heparin fixed doses — Competitive Intelligence Brief. https://druglandscape.com/ci/heparin-fixed-doses. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: